Droloxifene

Droloxifene

SCHEMBL4192

CC/C(=C(/c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ESR1ESR2

The experimentally established mechanism targets of Droloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 known ✓ P03372 12/20 0.87
ESR2 known ✓ Q92731 5/20 0.87
MEN1 O00255 4/20 0.87
TP53 P04637 4/20 0.87
KMT2A Q03164 4/20 0.87
CYP3A4 P08684 3/20 0.87
KDM4E B2RXH2 3/20 0.87
LMNA P02545 3/20 0.87
CYP1A2 P05177 3/20 0.87
CYP2D6 P10635 3/20 0.87
ALDH1A1 P00352 2/20 0.87
HIF1A Q16665 2/20 0.87
CYP2C9 P11712 2/20 0.87
MAPK1 P28482 2/20 0.87
GMNN O75496 1/20 0.87
TSHR P16473 1/20 0.87
ALOX12 P18054 1/20 0.87
NFKB1 P19838 1/20 0.87
CYP2C19 P33261 1/20 0.87
THPO P40225 1/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Droloxifene SCHEMBL4193 1.00 ESR1 (0.87) ESR1ESR2MEN1TP53KMT2A
Droloxifene SCHEMBL28121669 0.99 ESR1 (0.85) ESR1ESR2MEN1TP53KMT2A
Droloxifene SCHEMBL28121670 0.99 ESR1 (0.85) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL17164701 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL5328781 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL26077 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL10336277 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL6365 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL4019370 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A
Tamoxifen SCHEMBL178086 0.93 ESR1 (1.00) ESR1ESR2MEN1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9137 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
EP-4524131-A1 SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH AlonBio Ltd. (IL) 2025-03-19 EP claimed
US-12202803-B2 Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death ALONBIO LTD. (IL) 2025-01-21 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-12109219-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2024-10-08 US claimed
WO-2024162488-A1 PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN 주식회사 재인알앤피 2024-08-08 WO claimed
EP-4401780-A1 AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF University of Maryland, College Park (US) 2024-07-24 EP claimed
WO-2024026505-A2 DISRUPTION OF TELOCYTE ACTIVITY PATEL AMIT (US) 2024-02-01 WO claimed
US-20240002347-A1 SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH ALONBIO LTD. (IL) 2024-01-04 US claimed
US-20080176853-A1 e.g. N-(2-chloro-6-methylphenyl)-3-ethoxyacrylamide; protein (tyrosine and serine/threonine) kinase inhibitor; variety of conditions and diseases; antiproliferative, anticarcinogenic, antiinflammatory, antiallergenic agent; autoimmune and neurodegenerative disorders ABRAXIS BIOSCIENCE, INC. (US) 2008-07-24 US claimed
WO-2008076883-A2 TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS ABRAXIS BIOSCIENCE, INC. (US) 2008-06-26 WO claimed
WO-2008062466-A2 CINNAMIC ACID, VANILLIC ACID AND BENZOFURAN DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION AND CANCER RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2008-05-29 WO claimed
WO-2008039254-A2 RNA NANOPARTICLES AND NANOTUBES GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2008-04-03 WO claimed
WO-2007059116-A2 GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF ABRAXIS BIOSCIENCE, INC. (US) 2007-05-24 WO claimed
US-20060079472-A1 Methods for treating angiogenesis ANGIOSYN, INC. 2006-04-13 US claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed
US-5792798-A ADMINISTERING A TRIPHENYL ETHYLENES TO PREVENT VENOUS THROMBOSIS, HEART DISEASE AND AS ANTITUMOR AGENT ELI LILLY AND COMPANY (US) 1998-08-11 US claimed